Guardant Health closes the week at $150.03 — up 15% in seven days — with its co-founder selling aggressively into the strength and analysts still racing to catch up with the move.
The insider story is the clearest tension this week. Co-CEO and co-founder AmirAli Talasaz sold roughly 143,000 shares across multiple tranches on June 26 and 29, raising approximately $21 million at prices between $150 and $153. These are not small window-dressing transactions. The 90-day net figure across all insiders shows net selling of $40 million in value, even as the stock has climbed sharply. Talasaz's institutional holding has dropped to 1.42% of shares from a higher base, per the most recent filing. That level of founder selling at a multi-month high is worth watching, even if the stock's momentum has been undeniable.
Short sellers are quietly retreating rather than fighting the rally. Short interest has fallen 4.2% over the week to 9.6% of free float — still a meaningful position, but the direction of travel is clearly cover-and-step-aside. Borrow conditions are loosening in parallel: availability has expanded sharply to 2,190%, up 35% on the week, reflecting a significant increase in shares returning to the lending pool. Cost to borrow has eased to 0.44%, down from above 0.5% for most of the past month. The ORTEX short score has drifted lower all week, from 54.7 on June 19 to 50.7 — consistent with a squeeze-lite dynamic where shorts trim rather than add. Nothing in the borrow market suggests distress; conditions are loose and relaxing further.
Options positioning is slightly more cautious than the recent norm, but not dramatically so. The put/call ratio edged up to 0.75 at the close, just under one standard deviation above its 20-day average of 0.72. That's a mild tilt toward protection — call it selective hedging rather than a bearish conviction trade. The 52-week range runs from 0.43 to 1.43, so the current reading sits well within normal. Overall, options traders appear content to ride the momentum with modest downside insurance rather than aggressively position either way.
The Street continues to revise higher, and the pace has accelerated further this week. BTIG raised its target from $160 to $190 on July 1, while Bernstein reinstated coverage at Outperform with a $175 target on June 26 and Guggenheim lifted to $160 on June 29. That adds to a now-dense cluster of recent upgrades from Goldman, RBC, Mizuho, and Evercore that was the subject of last week's note. The consensus mean target has moved to $148 — now essentially in line with where the stock closed — while the freshest targets ($175–$190) remain well above the current price. Bulls point to Guardant's 50%-plus share in circulating genomic profiling and nearly 30% segment growth. Bears focus on PAMA reimbursement risk and a potential $100 million one-time revenue hit. The factor score on analyst recommendation divergence ranks at 100th percentile, an unusually clean sweep of bullish positioning; EPS 12-month forward growth ranks 99th percentile. Quality remains the weak spot — negative ROA and negative free cash flow margins underpin that bear case on profitability timing.
With Q2 earnings due July 30, the next month sets up as a direct test of whether the commercial ramp of the Shield colorectal screening test is converting at the pace the upgraded Street targets imply — and whether Talasaz's selling pressure at these levels reflects opportunistic planning or something more cautious about the near-term setup.
See the live data behind this article on ORTEX.
Open GH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
